• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·AKTS
Held by 1 Guru
Share

Aktis Oncology, Inc. Stocks

$ 18.52Last Updated 05.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 989.05M

$ 18.52
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.00%

Latest news

09.01.2026 15:00

Aktis Oncology IPO: Shares of the developer of radiopharmaceuticals for cancer have started trading

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is overvalued on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of AKTS is 33.3 and suggests 78.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 12:54

After Anthropic backed out of the deal, Amazon began considering a $7 billion acquisition of an AI startup

12.10.2026 12:04

Burry adjusted his bets on a market decline. Which stocks did he buy and sell?

12.10.2026 11:06

Oil prices fell after Trump's remarks about an "energy truce" between Russia and Ukraine

12.10.2026 10:45

The Hong Kong market is under pressure. Which stocks did the investor from “Shorting the Market” buy?

12.10.2026 10:38

Top Stories This Morning: Oil Prices Fall Following Trump's Statement; Amazon Shows Interest in Decart

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026